pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA
Vanda Pharmaceuticals Netherlands
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Netherlands is a pharma organization headquartered in Washington, USA. It trades on NYSE under ticker VNDA. Primary therapeutic focus areas include Generalized Pustular Psoriasis, Schizophrenia, Maj
Company details
- Status
- Public
- HQ
- 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
- Founded
- 2003
- Employees
- 600
- Programs
- 60
- Drugs
- 19
- Patents
- 96
Quick answer
Vanda Pharmaceuticals Netherlands is a pharma organization headquartered in Washington, USA. It trades on NYSE under ticker VNDA. Primary therapeutic focus areas include Generalized Pustular Psoriasis, Schizophrenia, Major Depressive Disorder, Circadian Rhythm Sleep Disorders, Insomnia. NovaPharmaNews links 60 clinical program(s), 5 drug profile(s), and 96 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (21), phase 2 (21), phase 1 (15).
Company snapshot
Vanda Pharmaceuticals Netherlands maintains 60 tracked programs across Generalized Pustular Psoriasis, Schizophrenia, Major Depressive Disorder, Circadian Rhythm Sleep Disorders, Insomnia, Bipolar Disorder, Bipolar I Disorder, Hypertension, Safety and Tolerability of Iloperidone, Parkinson Disease Psychosis, Acne Vulgaris, Acneiform Eruptions. Momentum score: 20/100 (30-day delta: n/a). Public reg
- 8 approved product(s) across US/EU regulatory metadata.
- 60 active pipeline program(s) linked via ClinicalTrials.gov.
- 96 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Vanda Pharmaceuticals Netherlands. Not investment advice.
Recent coverage
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Vanda Pharmaceuticals Netherlands.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Vanda Pharmaceuticals Netherlands.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Vanda Pharmaceuticals Netherlands?
-
Is Vanda Pharmaceuticals Netherlands publicly traded?
-
What drugs does Vanda Pharmaceuticals Netherlands develop or market?
-
What are the latest developments for Vanda Pharmaceuticals Netherlands?
-
What therapeutic areas does Vanda Pharmaceuticals Netherlands focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.